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procedure to be continuously delivered 
during the COVID-19 pandemic.1
Therefore, specific recom men-
dations have been released to 
reorganise the workflow of FMT 
during the pandemic to avoid the 
potential risk of transmission of 
severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) through 
the FMT procedure or the donor–
recipient faecal transfer.2 Briefly, these 
recommendations included the use 
of remote assessment of patients 
and donors whenever possible, the 
expansion of donor screening with 
questionnaires and laboratory testing 
aimed at excluding SARS-CoV-2 
infection, and the application of 
specific safety measures during the 
endoscopic FMT procedure.1,3
The SARS-CoV-2 vaccination 
campaign has started worldwide in the 
past few weeks. One major category of 
vaccines (developed both by BioNTech 
and Pfizer, and also by Moderna and 
the National Institute of Allergy and 
Infectious Diseases) is based on mRNA 
products that encode a genetically 
modified SARS-CoV-2 spike protein. 
These vaccines are promising, with 
93–95% efficacy and minimal side-
effects. An additional emerging class 
of vaccines, that uses a non-replicating 
adenovirus vector with SARS-CoV-2 
spike protein, including the ChAdOx1 
nCoV-19 University of Oxford and 
AstraZeneca vaccine, has also been 
given at least temporary authorisation 
in some countries (eg, Argentina, 
Brazil, and the UK, among others). 
Finally, various vaccine technologies, 
including live attenuated vaccines, are 
being investigated.
Overall, these efforts are expected to 
give a considerable boost to the fight 
against COVID-19. Consequently, an 
important discussion in the field of 
human tissue transfer is required, and 
specifically in FMT. We must consider 
what effect vaccination will have 
on FMT in clinical practice based on 
current knowledge and data.
The first question is whether there 
should be a waiting period between 
sample size. We were reassured that 
only four (7%) of 61 non-randomised 
organ preservation tumours were 
reported as ypT3. MRI reporting 
guidelines were provided in the 
protocol, supplemented by attendance 
of site radiologists at radiology 
training workshops to standardise 
reporting in both the TREC and STAR-
TREC studies.
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increases exponentially with age and 
the prevalence of comorbidity at 
the time of rectal cancer diagnosis 
is also shown to be age-related.3 It is 
argued that 6 months of follow-up 
is necessary to accurately describe 
the mortality risk of patients aged 
65 years or older who have total 
mesorectal excision surgery, and that 
this risk exceeds 10% for patients 
older than 75 years.3 Patients aged 
65 years or older who have an 
increased perioperative mortality risk 
might legitimately consider trading 
this upfront risk for a relatively safe, 
organ-preserving alternative, albeit 
one with a higher local failure rate of 
11% at 3 years.
We appreciate that there are 
controversies surrounding optimal 
staging of patients with small rectal 
cancers and Mathew presents cogent 
arguments to support the use of 
endorectal ultrasound, where the 
aim is to discriminate T1 tumours 
from T2 tumours. In the TREC study, 
eligible patients had biopsy-proven 
adenocarcinoma, not greater than 
stage T2 on MRI, with no evidence of 
mesorectal lymph node metastasis. 
Importantly, the multidisciplinary 
team considered that total mesorectal 
excision would be the standard 
treatment approach. When developing 
the TREC study, we specifically avoided 
over-reliance on discrimination 
between T1 and T2 tumours, as 
accuracy across multiple sites was 
inconsistent.4 In the TREC and STAR-
TREC studies, all organ-preserving 
treatment schedules incorporated 
radiotherapy to treat potential 
microscopic lymph node disease. With 
respect to the finding of ypT3 tumours 
in five (19%) of 27 patients randomly 
assigned to organ preservation, 
compared with only one (4%) of 
28 patients randomly assigned 
to total mesorectal excision, we 
believe that this finding reflects real-
world limitations of MRI staging for 
discrimination of T2 from T3a rectal 
tumours at the time of the study, 
compounded by a relatively small 
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and donor recruitment 
for FMT
Due to its clear benefits in the 
management of recurrent Clostridioides 
difficile infection, faecal microbiota 
transplantation (FMT) has been 
advocated by the gastroenterological 
community as a non-postponable 
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COVID-19, uncertainty remains 
regarding their effect on transmission 
of the virus. More specifically, there 
are no available data for the presence 
of SARS-CoV-2 in the faeces of 
individuals who have been vaccinated 
if exposed, and of the risk of faecal–
oral transmission of the virus. Finally, 
as we do not yet know how long 
vaccine immunity lasts, it would be 
difficult to predict the duration of 
the donor’s protection against the 
virus. These open questions prevent 
any recommendation to change or 
streamline the current indications 
for the screening of stool donors, as 
current data do not yet assure us with 
a satisfactory level of safety for FMT.
Irrespective of the above consid-
erations, because different steps of 
the FMT process (eg, the evaluation of 
donors and patients, the manipulation 
of faeces, the FMT procedure itself, 
and the follow-up of patients) 
could expose donors, patients, and 
physicians to SARS-CoV-2 infection, 
it is reasonable and wise to strongly 
encourage vaccination.
In conclusion, although the roll-
out of vaccines is expected to be a 
turning point in the pandemic, the 
alert level applied to the FMT work-
flow to prevent the transmission of 
SARS-CoV-2 cannot be reduced until 
further data emerges.
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SARS-CoV-2 vaccination and donor 
screening. In our latest consensus 
report on stool biobanking, a recent 
history (<2 months) of vaccination 
with a live attenuated virus was 
among the exclusion criteria for stool 
donors in case of a possible risk of 
transmission.4 For vaccines based on 
mRNA technologies (rather than live 
attenuated virus), it does not seem 
feasible that there would be a risk 
for transmission, and this exclusion 
criterion can be disregarded, as 
already suggested for blood donors.5 
Nonetheless, available vaccines have 
been associated with some adverse 
events, including fatigue, nausea, 
fever, headache, myalgia, arthralgia, 
and pain at the injection site, among 
others, which can last several days after 
the vaccination. As these symptoms 
can overlap with those assessed 
during donor screening (at the entry 
questionnaire and the day of each 
donation), it might be pragmatic to 
wait 7–10 days from vaccination before 
evaluating potential donors to avoid 
the risk of inappropriate rejection of 
candidates. It could also be reasonable 
to follow such an approach for vaccines 
based on viral vectors, as suggested in 
UK blood donation guidelines.6 Live 
attenuated virus vaccines are being 
developed and could become available 
for clinical use, but we still do not have 
data for risk of viral transmission with 
these candidate vaccines. Therefore, 
the safest approach might be to adhere 
to current guidelines for this type of 
vaccine and wait at least 2 months 
after vaccination before donor 
screening.4 At the initial evaluation, all 
potential donor candidates should be 
asked about SARS-CoV-2 vaccination 
and, if vaccinated, a window of time 
(the length depending on the type of 
vaccine) should elapse before moving 
forward with full screening (appendix).
Another question is whether donors 
who have been vaccinated require 
clinical and laboratory investigations 
for COVID-19 during screening. 
Although it is recognised that current 
vaccines are effective in preventing 
See Online for appendix
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inequity before the pandemic. But, 
COVID-19 has amplified the racial 
and ethnic health-care inequities 
that exist in an infrastructure that 
was not built to bridge these gaps, 
and now finds itself under pressure 
from an unprecedented global health 
crisis. Calls to rectify disparities in 
early cancer detection and prevention 
efforts are reassuring, particularly since 
it is anticipated that these will deepen 
without immediate action.1 However, 
these calls have primarily focused on 
cancers for which systematic screening 
recommendations already exist, such 
as colorectal cancer and breast cancer. 
There is one cancer in particular that 
regrettably continues to get little 
attention, despite being defined by 
striking racial and ethnic disparities in 
the USA: gastric cancer.
Gastric cancer disproportionately 
affects non-White racial and ethnic 
minority groups in the USA, especially 
non-Hispanic Black Americans, 
Hispanic Americans, Asian Americans, 
and other immigrant groups coming 
from countries with a high incidence of 
gastric cancer. A recent US population-
based analysis quantified this dispro-
portionate risk, reporting that, among 
the age group generally considered for 
cancer screening (age ≥50 years), there 
is an up to 14·5-times higher risk of 
non-cardia gastric adenocarcinoma—
the most common form of gastric 
cancer—in non-White racial or ethnic 
groups compared with non-Hispanic 
White people.2 In fact, the age-
adjusted incidence of gastric cancer 
is markedly higher than oesophageal 
cancer in all non-White racial or 
ethnic groups (appendix), and even 
exceeds that of colorectal cancer in 
certain groups (eg, Korean American 
men). Importantly, these comparisons 
probably under estimate the true 
burden of disease since early gastric 
cancer typically goes undiagnosed in 
the USA in the absence of systematic 
screening programmes.
In the USA, guidelines clearly 
delineate which populations are 
recommended to undergo screening 
for colorectal and oesophageal 
cancers. And, because there are 
guidel ines,  these preventive 
interventions are typically covered by 
insurance. Gastric cancer screening 
does not have such guidelines 
and insurance coverage, despite 
substantial evidence identifying 
high-risk groups and decision model 
analyses showing that endoscopy for 
gastric cancer screening in these high-
risk groups could be cost-effective.3 
Reflecting the mismatch between high 
disease burden in specific populations 
and inadequate  cancer-attenuating 
efforts, the norm in the USA is that 
gastric cancer is diagnosed in more 
advanced stages when symptoms 
prompt diagnostic investigations. 
When diagnosed in these late stages, 
there are no curative options and the 
prognosis is dismal; this should not be 
the norm. In countries where gastric 
cancer screening programmes exist, 
gastric cancer is more often diagnosed 
in an early (typically asymptomatic) 
stage before submucosal invasion, 
when endoscopic or surgical resection 
can be done with curative intent 
and is associated with greater than 
95% 5-year survival.4 According to 
modelling studies, the cost benefit of 
gastric cancer screening in the USA is 
predominantly driven by the increased 
probability of diagnosing gastric 
neoplasia at a stage when resection 
is typically curative.3 Moreover, 
there have been remarkable strides 
in advanced endoscopic expertise. 
Indeed, endoscopic resection of 
early gastric cancer is increasingly 
available in the USA,5 and achieves 
similar outcomes as in the east 
Asian countries that pioneered and 
perfected these techniques. In fact, 
these techniques were borne in 
response to, and in parallel with, the 
increased number of early gastric 
cancer cases being diagnosed as a 
result of implementing national 
gastric cancer screening programmes 
in Japan and South Korea.
Thus, a convincing argument can 
be made that gastric cancer early 
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Gastric cancer: 
a neglected threat to 
racial and ethnic 
minorities in the USA
The COVID-19 pandemic in the 
USA has exposed the pervasive 
inequities in health care for racial 
and ethnic minority groups. Health-
care professionals, especially those 
focused on cancer prevention and 
early detection, were aware of this 
